Chemokine receptor peptide vaccines for treatment and prevention of diabetes

Abstract

The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.

What is claimed is:  
     
         1 . A method of inducing an immune response against a chemokine receptor molecule in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule.  
     
     
         2 . The method of    claim 1   , wherein the chemokine receptor is CXCR3.  
     
     
         3 . The method of    claim 1   , wherein the immunogenic peptide is conformationally constrained.  
     
     
         4 . The method of    claim 1   , wherein the immunogenic peptide is cyclized.  
     
     
         5 . The method of    claim 1   , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.  
     
     
         6 . The method of    claim 1   , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.  
     
     
         7 . The method of    claim 1   , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.  
     
     
         8 . The method of    claim 1   , wherein the administration is parenteral.  
     
     
         9 . The method of    claim 1   , wherein the adjuvant is alum.  
     
     
         10 . A method of inhibiting recruitment of T cells to inflammation site in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor peptide from a extracellular region of a chemokine receptor molecule.  
     
     
         11 . The method of    claim 10   , wherein the chemokine receptor is CXCR3.  
     
     
         12 . The method of    claim 10   , wherein the immunogenic peptide is conformationally constrained.  
     
     
         13 . The method of    claim 10   , wherein the immunogenic peptide is cyclized.  
     
     
         14 . The method of    claim 10   , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.  
     
     
         15 . The method of    claim 10   , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.  
     
     
         16 . The method of    claim 10   , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHEDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.  
     
     
         17 . The method of    claim 10   , wherein the inflammatory response is associated with multiple sclerosis.  
     
     
         18 . A pharmaceutical composition comprising an adjuvant and an isolated immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule.  
     
     
         19 . The composition of    claim 18   , wherein the chemokine receptor is CXCR3.  
     
     
         20 . The composition of    claim 18   , wherein the immunogenic peptide is conformationally constrained.  
     
     
         21 . The composition of    claim 18   , wherein the immunogenic peptide is cyclized.  
     
     
         22 . The composition of    claim 18   , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.  
     
     
         23 . The composition of    claim 18   , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.  
     
     
         24 . The composition of    claim 18   , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.